Optimizing Trelegy Denial Management with Klivira Automation

The Impact of Trelegy Denials on Revenue Cycle

Trelegy, a common prescription for COPD and asthma, frequently triggers prior authorization requirements and subsequent denials due to formulary restrictions, step-therapy protocols, or insufficient clinical documentation. These denials, whether received via X12 835 for billed services or X12 277 for pre-service PA status, necessitate prompt and accurate processing to avoid write-offs and ensure patient access. The administrative burden of manually addressing these denials directly impacts staff time and operational costs, as highlighted by industry benchmarks from sources like the CAQH Index and MGMA Practice Operations and Cost Surveys.

Common Denial Triggers for Trelegy Prescriptions

Denials for Trelegy often stem from specific clinical and administrative hurdles. These can include failure to document prior-line therapy with preferred alternatives, lack of spirometry results supporting the diagnosis, or incomplete clinical notes justifying the prescription within payer-specific medical policies. Klivira's system is designed to identify these specific CARC/RARC codes and payer-specific denial texts, enabling targeted appeal strategies that address the root cause of the denial efficiently.

Klivira's Automated Trelegy Denial Workflow

• **Multi-channel Denial Ingestion:** Klivira captures Trelegy denials from X12 835 transactions, X12 277 claim status responses, payer portal notifications, and Da Vinci PAS `ClaimResponse` for PAS-conformant payers.
• **Automated Denial Reason Normalization:** CARC/RARC codes and payer-specific explanations are normalized into a uniform taxonomy, ensuring accurate categorization of Trelegy-related denials (e.g., step-therapy, medical necessity, documentation gaps).
• **Intelligent Appeal Packet Assembly:** For clinical necessity denials, Klivira automatically pulls relevant clinical documentation—such as spirometry results, prior-line therapy history, and physician notes—from the EMR via FHIR to construct a comprehensive appeal packet.
• **Timely Filing Enforcement:** The platform actively tracks payer-specific appeal windows for Trelegy, providing proactive alerts and ensuring appeals are submitted within critical deadlines to prevent lost revenue.
• **Feedback Loop for Upstream PA:** Klivira analyzes patterns in Trelegy denials by payer and reason, providing actionable insights to improve the accuracy of future prior authorization submissions for respiratory medications.

Essential Documentation for Trelegy Appeals

Successful appeals for Trelegy denials hinge on presenting a complete and compelling clinical narrative. Key documentation often includes detailed physician notes outlining the patient's diagnosis (e.g., COPD, asthma), severity of symptoms, and functional limitations. Evidence of prior-line therapy failures with alternative medications, spirometry test results (FEV1, FVC), and any relevant comorbidity information are critical. Klivira's automated documentation discovery via FHIR helps ensure these elements are systematically included in appeal submissions, reducing manual effort and strengthening the case.

Beyond Appeals: Proactive Trelegy PA Optimization

Effective Trelegy denial management extends beyond just appealing individual cases. Klivira's platform provides robust reporting and analytics that identify recurring denial patterns related to specific payers, formularies, or clinical scenarios. This intelligence feeds back into the upstream prior authorization process, enabling clinics and health systems to refine their initial PA submissions for Trelegy and other respiratory drugs, thereby reducing the likelihood of future denials and improving first-pass approval rates.